donate now The Fatty Liver Foundation

FATTY LIVER FOUNDATION MARKS WORLD LIVER DAY WITH LAUNCH OF ITS ANNUAL U.S. PATIENT SURVEY AMID BREAKTHROUGH THERAPIES

FATTY LIVER FOUNDATION MARKS WORLD LIVER DAY WITH LAUNCH OF ITS ANNUAL U.S. PATIENT SURVEY AMID BREAKTHROUGH THERAPIES

FLF unveils the third-year launch of “The Steatotic (Fatty) Liver Care in America: Patient Perspectives Research,” a pioneering nationwide initiative that empowers MAFLD/MASH patients to share their experiences and drive ongoing improvements in patient care

April 19, 2024; Boise, IDAHO — In observance of World Liver Day, the Fatty Liver Foundation (FLF) proudly announces the launch of this year’s "The State of Steatotic (Fatty) Liver Care in America: Patient Perspectives Research." This pivotal, nationwide survey comes at a transformative time with the introduction of Rezdiffra™, the first FDA-approved treatment in the U.S. for adults with metabolic dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver fibrosis, used in conjunction with diet and exercise.

Read more

A New Dawn in Liver Health: Fatty Liver Foundation Applauds Breakthrough FDA Approval of REZDIFFRA™ (resmetirom) for MASH Treatment

A New Dawn in Liver Health: Fatty Liver Foundation Applauds Breakthrough FDA Approval of REZDIFFRA™ (resmetirom) for MASH Treatment

 

BOISE, ID – MARCH 14, 2024 – The Fatty Liver Foundation (FLF) heralds a significant milestone in the field of liver health with the U.S. Food and Drug Administration’s (FDA) approval of REZDIFFRA™ (resmetirom), developed by Madrigal Pharmaceuticals, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). This landmark approval paves the way for the first-ever medication for adults with fibrosis stage 2 or 3 due to MASH, marking a watershed moment in the pursuit of effective treatments. REZDIFFRA™ has been recognized by the FDA through breakthrough therapy and priority review designations for this crucial indication.

Read more

Fatty Liver Foundation and Society for Sober Liver Survival Forge Groundbreaking Collaboration in the Fight Against Liver Diseases

FLF and Sober Liver Embark on a Collaborative Mission to Revolutionize Liver Health Support and Advocate for Patients Nationwide

 

BOISE, ID & AURORA, CO / NOVEMBER, 28, 2023 – In a major step forward for liver health, the Fatty Liver Foundation (FLF) and the Society for Sober Liver Survival (Sober Liver) are pleased to announce their formal collaboration through a Memorandum of Understanding (MOU). This collaboration unites the two organizations in the fight against liver diseases, especially Metabolic and Alcohol-Associated Liver Disease (MetALD), a condition that has gained increased recognition in the medical community following a recent change in disease nomenclature by hepatology experts in June 2023.

Read more

Fatty Liver Foundation Celebra el Día Internacional de la EHNA (Esteatohepatitis No Alcohólica)

Cerrando la brecha de concientización para tomar medidas para la Salud del Hígado

8 de Junio, 2023; Boise, IDAHO ─ The Fatty Liver Foundation (FLF), una organización líder en la defensa de los pacientes  con enfermedades hepáticas  en los Estados Unidos, invita a todos los estadounidenses a celebrar este 8 de Junio como el Día Internacional de la Enfermedad de Hígado Graso No Alcohólico (EHGNA) y la Esteatohepatitis No Alcohólica (EHNA), Destacando estas condiciones, la FLF tiene como objetivo inspirar estrategias de detección temprana, prevención y tratamiento efectivo, todo en un esfuerzo por mejorar los estándares de la salud de los pacientes.

Read more

Shining a Spotlight and Taking Action for Liver Health: Fatty Liver Foundation Marks International NASH Day

Bridging the Awareness Gap: Step Up for NASH

June 8, 2023; Boise, IDAHO The Fatty Liver Foundation (FLF), a leading patient advocacy organization championing liver health in the United States, invites Americans to participate in marking International NASH Day on Thursday, June 8th. This significant day is devoted to enhancing awareness about non-alcoholic fatty liver disease (NAFLD) and its severe form, non-alcoholic steatohepatitis (NASH). By shining a spotlight on these conditions, FLF aims to inspire early detection, prevention, and effective treatment strategies, all in a bid to ultimately improve patient outcomes.

Read more

Fatty Liver Foundation Partners With Secure AI Labs To Empower NAFLD and NASH Community With New Patient-Facing Tool

FLF and SAIL are stepping up to NASH by developing a risk stratification tool with a 77% detection rate for NAFLD.

 

CAMBRIDGE, MA & BOISE, ID / ACCESSWIRE / JUNE, 8, 2023 - The Fatty Liver Foundation (FLF), a leading patient advocacy organization, today announced the development of its AI Fatty Liver Risk Stratification Tool, in conjunction with a collaborative health data research software provider Secure AI Labs (SAIL).

Read more

Pivotal FDA Advisory Committee Meeting: Fatty Liver Foundation Advocates for Approval of Groundbreaking NASH Treatment

Co-founder and CEO Wayne Eskridge addresses the FDA Gastrointestinal Drugs Advisory Committee (GIDAC), representing millions of NASH patients awaiting a much-needed treatment option

May 19, 2023; Boise, IDAHO — Today marks a significant moment in the fight against non-alcoholic steatohepatitis (NASH) as the U.S. Food and Drug Administration’s Gastrointestinal Drugs Advisory Committee (GIDAC) convenes its public meeting to assess the New Drug Application for obeticholic acid (OCA), a potential new treatment option for NASH. As this discussion could significantly influence future FDA decisions, millions of NASH patients across the U.S. are keenly observing its progress. The Fatty Liver Foundation (FLF) remains resolute in advocating for their needs. The urgency is clear – there is a dire unmet need in NASH treatment. Now more than ever, FLF is unwavering in its commitment to vigorously advocate for these patients.

Read more

FATTY LIVER FOUNDATION EXPRESSES CONCERNS ABOUT ICER’S EVIDENCE REPORT ON NASH TREATMENTS

Co-founder and CEO Wayne Eskridge highlights concerns about the underestimation of NASH impact and implications for obeticholic acid and resmetirom

 

April 28, 2023; Boise, IDAHO Wayne Eskridge, Co-Founder and CEO of the Fatty Liver Foundation (FLF), is urging a re-evaluation of the Institute for Clinical and Economic Review (ICER) evidence report on obeticholic acid and resmetirom for the treatment of nonalcoholic steatohepatitis (NASH). Eskridge, diagnosed with liver disease in 2010 and cirrhosis in 2015, established FLF to support approximately 20,000 patients with nonalcoholic fatty liver disease (NAFLD) and its progressive stage, NASH.

Read more

FATTY LIVER FOUNDATION’S ANNUAL NATIONAL SURVEY AIMS TO RESHAPE NAFLD/NASH CARE IN THE U.S.

FLF unveils the second-year launch of The State of NAFLD/NASH Care in America, a pioneering nationwide initiative that empowers NAFLD/NASH patients to share their experiences and drive ongoing improvements in patient care

 

April 10, 2023; Boise, IDAHO — The Fatty Liver Foundation (FLF) today announces the second-year launch of The State of NAFLD/NASH Care in AmericaTM, a pioneering national initiative that aims to make a significant impact within the NAFLD/NASH patient community. This initiative surveys the real-life experiences of adults with NAFLD/NASH across the United States, promoting the ongoing development and implementation of practical solutions to improve diagnosis, treatment, care, and support for those affected by these conditions.

Read more

Fatty Liver Foundation Announces Preliminary Findings From State of NAFLD/NASH Care in America Patient Survey

The Fatty Liver Foundation (FLF) is excited to announce preliminary findings from The State of NAFLD/NASH Care in America™, a first-of-its-kind national initiative that aims to make a big impact within the NAFLD/NASH community by surveying the lived experiences of adults with NAFLD/NASH in the United States and fostering the continuous development and integration of actionable solutions to improve the diagnosis, treatment, care, and support for people with NAFLD/NASH.

Read more

connect